Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human... see more

TSXV:CZO - Post Discussion

Ceapro Inc > RE:If you Vote yes
View:
Post by prophetoffactz on Jan 08, 2024 1:34pm

RE:If you Vote yes

"I have to agree. Gilles should buy significant amount of shares or get compensated solely on value creation in order to demonstrate real commitment and not just draining of shareholders money."

He's added to his holdings over time. As of the Information Circular last year he held 1,739,000 shares and 820,000 options. He's dedicated the most important years of his career to this company. This is his baby. In terms of personal, financial and professional commitment it has been strong. Gilles has never sold a single share and how many CEO's can say that over a decade? 

We've been in the worst bear market in history for biotech. Price has meant little in terms of performance. CZO's main client went missing during a once a decade reorganization, for sake of argument; but is expected to return. CZO is in a proposed merger at the moment with full details expected to be released around Jan. 31, 2024. The price has been affected by factors outside of Gilles control. Gilles has convinced arguably the most important biotech executive in Canada to join the Board of Directors and become Chairman and he is "thrilled".
Be the first to comment on this post